Enanta Pharmaceuticals, Inc. (ENTA) Cash Flow Statement

The sub-1.0 OCF/NI ratios (0.35 in 2025Q4, 0.51 in 2026Q3, 0.55 in 2026Q2) indicate that reported losses overstate cash consumption, with the ~$3.7M–$4.7M quarterly stock-based compensation addback and roughly $1.2M of D&A bridging most of the gap. Because Enanta's revenue is milestone- and royalty-based with gross margins at or near 100%, the accrual profile appears to be driven more by expense recognition and payment timing than by inventory or receivables mechanics — implying the quality of the OCF shortfall is unusually dependent on non-cash addbacks rather than genuine operating cash absorption.

The roughly 67% reduction in quarterly FCF outflow is real and material, but the path is not monotonic — 2026Q3's net loss widened sequentially to -$19.5M from -$13.1M, so the FCF trend reflects quarter-to-quarter expense and timing variance rather than a clean trajectory. The improvement correlates closely with the ~38% R&D reduction identified in prior analysis rather than any revenue recovery, which suggests the burn trajectory is a function of discretionary spend control and could reverse if pipeline commitments resume.

The same line item swung from -$2.9M in 2026Q1 to +$2.5M in 2026Q3 and +$9.2M in 2024Q4, producing extreme quarter-to-quarter OCF volatility that appears consistent with the receipt and recognition of contract milestones rather than a structurally tightening operating cycle. Excluding the 2025Q3 outlier, cumulative working capital contributions across the other nine quarters are comparatively modest, so investors should not read the single positive OCF print as evidence of improving collections or payables management; the supplied data does not disclose receivable aging or contract asset balances, which warrants further investigation.

Roughly $30.3M of cumulative capex across 2024Q2–2025Q1 has given way to approximately $0.16M over the last three quarters, which appears consistent with the completion of a prior lab build-out rather than a sudden collapse in operating needs. For a royalty-model business this low capital intensity aligns with the near-100% gross margin economics, yet the sustained gap between $1.2M of quarterly depreciation and negligible reinvestment suggests the physical research platform is being consumed without replacement — a pattern that may constrain future pipeline productivity.

That ~$107M divergence decomposes largely into roughly $48.5M of cumulative stock-based compensation, about $9.3M of D&A, and the lumpy net working capital timing discussed above — meaning the cash reality is materially less severe than the accounting loss profile, but the cushion is a function of non-cash compensation and payment timing rather than operating performance. The supplied data contains no cash balance, debt, or maturity information, so the implied funding runway cannot be assessed here; investors should monitor the balance sheet alongside these flows to determine how many quarters of burn the current liquidity position supports.